FONT-SIZE Plus   Neg

CVS Caremark Reaches $11 Mln Settlement With US DoJ For Drug Law Violations

The U.S. Department of Justice announced Wednesday that drug store chain CVS Caremark Corp. (CVS) has agreed to pay a fine of $11 million to settle civil penalty claims involving violations of Controlled Substances Act. This is one of the largest settlements ever paid for record-keeping violations by a retail pharmacy chain related to controlled pharmaceuticals.

The settlement was announced by U.S. Attorney for the Western District of Oklahoma Sanford Coats. CVS acknowledged that its stores must comply with the record-keeping requirements, but did not admit liability.

"The abuse of prescription drugs is a well-documented epidemic inflicting devastating, long-term, effects on individuals, families, and entire communities. To combat this problem, it is essential that those who dispense controlled substances comply with DEA's record-keeping requirements," Coats said in a statement.

The settlement resolves allegations that the company's Oklahoma pharmacies violated the Controlled Substances Act by failing to keep proper records of pharmacy drug sales.

The Act calls for pharmacies to document each transaction that involves controlled substances or powerful prescription drugs, along with the U.S. Drug Enforcement Administration or DEA, registration numbers of the doctors prescribing those drugs.

Each DEA registrant, including pharmacies, is required to maintain complete and accurate records of each substance manufactured, received, sold, delivered, dispensed or otherwise disposed of by the registrant for two years.

The process ensures that dispensers of prescription drugs remain accountable and these drugs are not illegally diverted to addicts and street dealers. The DoJ noted that abuse of prescription drugs is one of the most critical issues it faces currently.

The Woonsocket, Rhode Island-based company was charged of using dummy registration numbers for prescriptions, and filling prescriptions written by doctors whose DEA registrations were no longer valid. These violations occurred between October 2005 to October 2011 at two CVS pharmacies in Oklahoma.

The Acting Special Agent in Charge of the DEA Dallas Field Division, Daniel Salter, said, "This settlement reinforces the responsibilities of all pharmacies to prevent the diversion of dangerous drugs. This case highlights DEA's steadfast resolve to combat the growing prescription drug abuse problem in this country by ensuring that all DEA registrants, including nationwide pharmacy chains, are in compliance with the law. This is vital to protect public health and keep our communities safe."

CVS closed Wednesday's regular trading session at $54.13, down $1.11 or 2.01% on a volume of 6.75 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Shares of Philips Electronics NV were gaining around 3 percent in the early morning trading in Amsterdam after the Dutch consumer electronics giant reported Monday a higher profit in its third quarter driven by margin strength with improved performance in its segments. Consolidated comparable sales growth was 2 percent, driven by 5 percent increase in HealthTech portfolio. AT&T announced a definitive agreement to purchase Time Warner in a stock-and-cash transaction valued at $107.50 per share. This purchase price implies a total equity value of $85.4 billion and a total transaction value of $108.7 billion, including Time Warner's net debt. AT&T expects the deal to close before year-end 2017. Chipmaker Qualcomm is reportedly in talks with NXP Semiconductor NV (NXPI) for a possible acquisition, reports said. According to Bloomberg, negotiations are on with a probable price of $110 t $120 per NXP share. The deal would value NXP at around $34.7 billion.
comments powered by Disqus
Follow RTT